Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033085 · ClinicalTrials.gov registry record · Phase 2
Ondansetron for the Treatment of Cocaine Dependence - 1
A Phase 2 study of Cocaine-Related Disorders and Drug Administration Schedule, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00033085: Completed Phase 2 study of Cocaine-Related Disorders and Drug Administration Schedule, sponsored by National Institute on Drug Abuse (NIDA).
NCT00033085 is a Phase 2 study of Cocaine-Related Disorders and Drug Administration Schedule that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 60 participants, roughly in line with the 61-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033085, a Phase 2 study of Cocaine-Related Disorders and Drug Administration Schedule, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the efficacy and safety of ondansetron to reduce cocaine use in subjects with cocaine dependence.
Conditions Studied
Interventions
- DRUG Ondansetron
Study Locations (1)
Texas
- University of Texas Hlth Sci Ctr San Ant - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-05 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
What the finished NCT00033085 record still lists
NCT00033085 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 61-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target.
The record links to 2 conditions, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Ondansetron is the first listed.
NCT00033085 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00033085 about?
NCT00033085 is a clinical study titled "Ondansetron for the Treatment of Cocaine Dependence - 1". The purpose of this study is to assess the efficacy and safety of ondansetron to reduce cocaine use in subjects with cocaine dependence.
What is the current status of trial NCT00033085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-05. Estimated completion is 2002-12.
What conditions does trial NCT00033085 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders, Drug Administration Schedule.
What interventions are being tested in trial NCT00033085?
The interventions under investigation include: Ondansetron (DRUG).
Who is sponsoring clinical trial NCT00033085?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00033085 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00033085's enrollment target sits among peer trials
60 6th of 15 higher than 10 of 15 other Cocaine-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
COMPLETED · Phase 2
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Pharmacological Modulation of Cocaine Effects - 1
COMPLETED · Phase 2
-
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3
COMPLETED · Phase 2
-
Risperidone Treatment in Dually-Diagnosed Individuals - 2
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia